TrialStat EDC

Fast, Compliant, Fully Unified – EDC + IWRS + ePRO + Coding

TrialStat Portal

Real-Time Data & Analytics | Make Study Decision Sooner

Don't Settle For Standard EDC Technology & Services

With TrialStat EDC you'll have your studies up and running quicker, capture your study data more efficiently with fewer errors and reduce your overall study costs.

We're Supporting COVID-19 Research

In times of crisis we all need to step up and help. Effective immediately, we are offering TrialStat’s eClinical Platform and Data Analytics Portal at discounted rates to researchers working on solutions related to COVID-19. With a focus on ease of use, speed of implementation, and real-time data analytics, TrialStat’s data capture suite enables fast study start up and ensures all stakeholders have relevant, customized, timely insight into all aspects of study data and areas of risk or potential delays. We welcome the opportunity to collaborate with our industry colleagues on the path to treatments or cures – please contact to learn more about this program.

From the entire TrialStat team, we wish you and yours good health as our industry and our communities work together to navigate this outbreak over the coming weeks and months. Thank you for #StayingHome and #FlatteningTheCurve!

Our Latest COVID-19 Research News

Moderna publishes Phase III Covid-19 vaccine study protocol as trial enrolls more than 80% of participants

Excerpt from the Article: The company said at its R&D day that the Phase III COVE trial of mRNA-1273 had enrolled 25,296 of its planned 30,000 participants, while slightly more than 10,000 had received the first and second doses of the vaccine. One of the most closely watched Phase III Covid-19 vaccine trials is already…
Read More

Ufovax Announces Its Self-Assembling NanoParticles as the Next-Generation Vaccine Solution for COVID-19

Excerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–Ufovax, LLC, (Ufovax), a vaccine biotechnology company based on the patented One-component Self-Assembling protein NanoParticle® (1c-SApNP®) vaccine design and manufacturing platform invented by Associate Professor Jiang Zhu, PhD, of Scripps Research (La Jolla, CA), announced the advancement toward Phase I clinical trials of its next-generation SARS-CoV-2 (aka “COVID-19”)…
Read More

New Coronascape tool will help unlock big-data insights for COVID-19

Excerpt from the Article: Scientists at Sanford Burnham Prebys Medical Discovery Institute today announced they have released Coronascape (, a customized version of the Metascape bioinformatics platform that removes big-data analysis hurdles for biologists. Coronascape will enable scientists to interpret the growing body of big data related to COVID-19. More than 23,000 papers about COVID-19…
Read More

Equillium Announces Successful Completion of FDA Pre-IND Meeting Enabling Advancement of Itolizumab into a Potential Registration Study as a Treatment for Hospitalized COVID-19 Patients

Excerpt from the Press Release: LA JOLLA, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced it has completed a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) under the Coronavirus Treatment Acceleration Program (CTAP). The FDA provided…
Read More

Ask Us Anything In Clinical Trials – Data Management Tools We Love and Hate To Use

Our third episode in the Ask Us Anything In Clinical Trials virtual networking series. Heather and Christopher along with their guests dive into a discussion around the Data Management tools we love and hate to use, as well as how data management is changing under the evolving conditions brought on by the pandemic. If you…
Read More

Illumina awarded NIH funding for COVID-19 test that runs 3,000 samples at once

Excerpt from the Article: San Diego gene sequencing giant Illumina has secured government funding for a COVID-19 test that can detect the novel coronavirus in thousands of samples at once, according to an announcement this week from the National Institutes of Health. The NIH awarded nine companies a total of $129 million to develop rapid,…
Read More

Vaxart’s Oral COVID-19 Vaccine Candidate Induces Potent Systemic and Mucosal Immune Responses in Preclinical Studies

Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) — Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced pre-publication of a manuscript titled “Preclinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection.”…
Read More

Argentina’s IVERCAR Ivermectin & Carrageenan Study Shows Positive Results Targeting COVID-19

Excerpt from the Article: Based in the southern end of Greater Buenos Aires, Argentina, Eurnekian Public Hospital recently sponsored a clinical trial targeting COVID-19 called the IVERCAR study. The sponsor was joined by other local hospitals acting as trial site organizations. With study results in, the Argentinian group has discovered that while in the control group,…
Read More

Prominent biotech leaders release Covid-19 guidelines calling for FDA independence, data transparency

Excerpt from the Article: WASHINGTON — A group of prominent biotech CEOs are calling on their peers and the federal government to hold themselves to the highest standards when it comes to developing and reviewing Covid-19 treatments. Among their demands: That biotech companies don’t simply release clinical trial data in press releases, and that federal…
Read More

Translate Bio and Sanofi’s COVID-19 Vaccine Positive in Animal Studies

Excerpt from the Article: In a regulatory filing with the U.S. Securities and Exchange Commission (SEC), Translate Bio indicated that the COVID-19 vaccine it is developing with Paris-based Sanofi induced an immune response in non-human studies. The companies expect to begin human clinical trials in November. On June 23, Sanofi Pasteur, the vaccines business unit…
Read More

HiFiBiO Therapeutics Submits IND Application for Fully Human SARS-CoV-2 Neutralizing Antibody for the Treatment of COVID-19 Patients

Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–HiFiBiO Therapeutics, a multinational biotherapeutics company focused on the development of novel antibodies for immunomodulation, announced today the submission of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) for a novel SARS-CoV-2 neutralizing antibody for the treatment of COVID-19 patients. The highly…
Read More

Sorrento Announces FDA IND Filing Today for COVI-GUARD Neutralizing and High Potency Antibody Against SARS-CoV-2

Excerpt from the Press Release: SAN DIEGO, Aug. 19, 2020 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced that it is filing an investigational new drug application (IND) for COVI-GUARD (STI-1499) for hospitalized COVID-19 patients today. Sorrento has previously received guidance from the FDA in response to a pre-IND meeting package and believes…
Read More

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?